Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.

Lancet. 2015 Oct 3;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1. Epub 2015 Jul 23.

2.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.

Lancet. 2015 Oct 3;386(10001):1353-61. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30.

3.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.

4.

Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine.

Bredholt T, Ersvær E, Erikstein BS, Sulen A, Reikvam H, Aarstad HJ, Johannessen AC, Vintermyr OK, Bruserud Ø, Gjertsen BT.

BMC Pharmacol Toxicol. 2013 Jul 11;14:35. doi: 10.1186/2050-6511-14-35.

5.

Flotillins as regulators of ErbB2 levels in breast cancer.

Pust S, Klokk TI, Musa N, Jenstad M, Risberg B, Erikstein B, Tcatchoff L, Liestøl K, Danielsen HE, van Deurs B, Sandvig K.

Oncogene. 2013 Jul 18;32(29):3443-51. doi: 10.1038/onc.2012.357. Epub 2012 Aug 6.

PMID:
22869152
6.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.

Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.

7.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R.

Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.

8.

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S.

J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039. Review.

PMID:
20956824
9.

Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment.

Erikstein BS, Hagland HR, Nikolaisen J, Kulawiec M, Singh KK, Gjertsen BT, Tronstad KJ.

J Cell Biochem. 2010 Oct 15;111(3):574-84. doi: 10.1002/jcb.22741.

10.

Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB.

Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT.

Leuk Res. 2010 Jan;34(1):77-84. doi: 10.1016/j.leukres.2009.09.005. Epub 2009 Sep 27.

PMID:
19786302
11.

Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy.

Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bøhn M, Erikstein B, Helland A, Børresen-Dale AL, Fosså SD.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1163-71.

PMID:
17336217
12.

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.

Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J.

Ann Oncol. 2007 Apr;18(4):694-700. Epub 2007 Feb 13.

13.

Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.

Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91.

14.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.

15.

Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.

Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G.

Int J Cancer. 2006 Jun 1;118(11):2877-81.

16.

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G.

J Clin Oncol. 2005 Aug 1;23(22):5126-37. Epub 2005 Jun 27.

17.

Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.

Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA.

Clin Pharmacokinet. 2004;43(8):529-38.

PMID:
15170367
18.
19.

Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study.

Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fosså SD.

Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1397-404.

PMID:
12873686
20.

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study.

Söreide JA, Varhaug JE, Fjösne HE, Erikstein B, Jacobsen AB, Skovlund E, Kvinnsland S.

Eur J Surg Oncol. 2002 Aug;28(5):505-10.

PMID:
12217302
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk